Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.
EnVivo taps former Millennium head as CEO
Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company, will leave to serve as president and CEO of EnVivo Pharmaceuticals, which is focused on a late-stage CNS program for Alzheimer's and schizophrenia. Just two months after leaving Millennium, where she spent 8 years and led the company through Takeda's $8.8 billion acquisition, Dunsire said she is moving to the fast-growing drug developer in Watertown, MA. Story | Release
|
Biotech
> Anavex Life Sciences has appointed Dr. Christopher U. Missling as CEO. Previously, Missling was the chief financial officer of Curis ($CRIS) and ImmunoGen ($IMGN). Release
> Clarus Therapeutics announced two new hires: Dr. Theodore Danoff and Dr. Wael Salameh will fill the newly created posts of VP clinical development & chief medical officer and VP medical affairs & chief scientific officer, respectively. Danoff has worked previously with Endo Pharmaceuticals ($ENDP), GlaxoSmithKline ($GSK) and SmithKline Beecham; and Salameh was previously with Genentech, Quest Diagnostics ($DGX) and Telome Health. Release
> MediStem, formerly MediStem Laboratories, appoints John Salvador chief operating officer. Release
> Dr. Mark Walker steps up as East Coast-based field technical director for primate researchers SNBL USA. Release
> Melior Discovery appoints Dr. Gregory Gatto, the scientific founder of Biolucidation, as senior director of behavioral pharmacology as part of the company's acquisition. Release
> Robert Finn has been named the executive editor of the Accelerated Cure Project for Multiple Sclerosis' Multiple Sclerosis Discovery Forum. Release
> Philadelphia-based Aphena Pharma Solutions appoints Kevin Kerchner CEO. Release
> Christopher Barry has joined the Leukemia & Lymphoma Society Canada as its new president. Release
> Arch Therapeutics has appointed Alan Barber as chief financial officer. Barber has served as the chief financial officer of Arch Biosurgery since August 2008. The company has also appointed William Cotter as COO. Cotter has served as an adviser for Arch Therapeutics since 2011. Release
Pharma
> Eli Lilly ($LLY) CEO John Lechleiter is returning to work after recovering from surgery. Item
> ISA Pharmaceuticals B.V. has appointed Dr. Jan Fagerberg as chief medical officer and Dr. Jens Hennecke as chief business officer and advisor. Ronald Loggers will also step down from the board of directors and assume the role of acting CEO, while Gerard Platenburg will become chief operating officer. Release
> Kinex Pharmaceuticals has appointed Flint D. Besecker as chief financial officer and executive vice president. Besecker has been an investor and board director of Kinex since 2011. Release